{
  "version": 2,
  "updated": "2026-06-24",
  "description": "Knowledge Hub article manifest. Consumed by /js/knowledge-feed.js on the blog index and featured block. Newest published articles first.",
  "categories": [
    {"slug": "cross-border-marketing", "label": "Cross-Border Marketing"},
    {"slug": "city-corridors", "label": "City Corridors"},
    {"slug": "family-offices", "label": "Family Offices"},
    {"slug": "operators", "label": "Operators"},
    {"slug": "medtech-biotech", "label": "Medtech and Biotech"},
    {"slug": "industrials-engineering", "label": "Industrials and Engineering"},
    {"slug": "cyber", "label": "Cyber"},
    {"slug": "wealth-migration", "label": "Wealth Migration"}
  ],
  "articles": [
    {
      "slug": "marketing-in-usa-for-eu-companies",
      "title": "Marketing in the USA for EU companies: why strong firms fail and what to avoid.",
      "excerpt": "Why EU companies fail when they translate the home-market argument, what US buyers judge first, and what to rebuild before ads or distributors.",
      "category": "cross-border-marketing",
      "published": "2026-06-24",
      "score_minutes": 14,
      "featured": true,
      "status": "published",
      "image": "/images/generated/gma-eu-companies-us-marketing-failure-2026-06-24.png",
      "image_alt": "European export marketing pack beside US buyer evaluation documents on a procurement desk"
    },
    {
      "slug": "cross-border-wealth-migration-us-2026-report",
      "title": "Cross-border wealth migration into the US: a 2026 report.",
      "excerpt": "How capital reroutes from London, Hong Kong, Zurich, Singapore, and Dubai, and what the American-facing story has to carry.",
      "category": "wealth-migration",
      "published": "2026-04-24",
      "score_minutes": 25,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "five-cities-us-entry-comparison",
      "title": "Five cities meet the US filter: where they differ, where they break the same way.",
      "excerpt": "How Dubai, Singapore, Hong Kong, Zurich, and London break at the US border, with rebuilds by city and buyer type.",
      "category": "city-corridors",
      "published": "2026-04-24",
      "score_minutes": 27,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "geneva-biotech-medtech-us-commercialization",
      "title": "Geneva biotech and medtech crossing into US commercialization: where the Swiss frame breaks.",
      "excerpt": "Why Swiss regulatory posture does not substitute for US payer, KOL, and procurement signals.",
      "category": "medtech-biotech",
      "published": "2026-04-24",
      "score_minutes": 18,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "dach-mittelstand-industrials-engineering-us-entry",
      "title": "DACH Mittelstand meets US procurement: where the engineering frame breaks.",
      "excerpt": "Why precision language scores as process avoidance to US procurement, and what to rebuild first.",
      "category": "industrials-engineering",
      "published": "2026-04-24",
      "score_minutes": 14,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "london-cyber-medtech-us-market-entry",
      "title": "London cyber and medtech crossing into the US: where the sales story breaks.",
      "excerpt": "Why UK government references do not substitute for US proof in federal, Fortune 500, and commercial channels.",
      "category": "cyber",
      "published": "2026-04-24",
      "score_minutes": 16,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "london-non-dom-reform-us-corridor",
      "title": "London, the non-dom reform, and the US corridor: what actually needs to land first.",
      "excerpt": "What the American-facing commercial story needs to carry as family-office capital re-sequences through the US corridor.",
      "category": "wealth-migration",
      "published": "2026-04-24",
      "score_minutes": 15,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "hong-kong-industrials-technical-b2b-us-entry",
      "title": "Hong Kong industrials and technical B2B meet the US: where the sales story breaks.",
      "excerpt": "Why the Greater China credibility signal does not carry to US procurement and commercial buyers.",
      "category": "industrials-engineering",
      "published": "2026-04-24",
      "score_minutes": 15,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "hong-kong-wealth-migration-us-2026",
      "title": "Hong Kong wealth migration into the US: why the holding brand becomes the bottleneck.",
      "excerpt": "What needs to change in the American-facing brand and commercial story as Hong Kong private capital scales US exposure.",
      "category": "wealth-migration",
      "published": "2026-04-24",
      "score_minutes": 15,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "singapore-family-offices-us-expansion",
      "title": "Singapore family offices and US expansion: why the holding brand is the bottleneck.",
      "excerpt": "How US intermediaries score the Singapore holding brand differently, and what has to be rebuilt before co-investment activity scales.",
      "category": "family-offices",
      "published": "2026-04-24",
      "score_minutes": 14,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "singapore-medtech-biotech-us-entry",
      "title": "Singapore medtech and biotech hit the US: where the commercial story breaks.",
      "excerpt": "Why strong science and IP often misfire at US KOL, payer, and website, offer, proof, and follow-ups.",
      "category": "medtech-biotech",
      "published": "2026-04-24",
      "score_minutes": 14,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "zurich-medtech-biotech-us-entry-playbook",
      "title": "Zurich medtech and biotech crossing into the US: what actually needs to land first.",
      "excerpt": "Why Swiss proof architecture does not land for US commercial buyers, and how to rebuild the story.",
      "category": "medtech-biotech",
      "published": "2026-04-24",
      "score_minutes": 15,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "swiss-engineering-commercial-translation-us",
      "title": "Swiss engineering meets US commercial buyers: where the translation breaks.",
      "excerpt": "Why engineer-written positioning fails at the border even when the underlying product is strong.",
      "category": "industrials-engineering",
      "published": "2026-04-24",
      "score_minutes": 17,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "dubai-family-office-us-expansion-2026",
      "title": "Dubai family offices and US expansion: why the holding brand is the bottleneck.",
      "excerpt": "How DIFC-based family offices rebuild their US-facing brand for the American co-investor and intermediary.",
      "category": "family-offices",
      "published": "2026-04-23",
      "score_minutes": 14,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "difc-infrastructure-operators-us-procurement",
      "title": "DIFC infrastructure credentials do not score to the US procurement officer.",
      "excerpt": "Why regional infrastructure weight does not translate to US federal and state procurement officers.",
      "category": "operators",
      "published": "2026-04-23",
      "score_minutes": 15,
      "featured": false,
      "status": "published"
    },
    {
      "slug": "why-american-buyers-judge-foreign-brands-differently",
      "title": "Why American buyers interpret your business differently than the market that built it.",
      "excerpt": "Why home-market brands do not translate, what American buyers evaluate, and the register gap that costs international firms time.",
      "category": "cross-border-marketing",
      "published": "2026-04-19",
      "score_minutes": 12,
      "featured": false,
      "status": "published"
    }
  ]
}